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Evaluating New Health Technologies and Disease Burden in Developed
CountriesTo the Editor—We read with interest the article by Martino and
colleagues published recently in Value in Health. Their study exam-
nes the relationship between the reporting of new and emerging
ealth technologies uploaded onto the EuroScan database (from
000 to 2009) and the burden of disease in 17 developed countries,
ost of them in Europe [1]. The motivation for their study is the
ngoing greater use of disease burden measures in research and
nnovation priority setting and, in particular, horizon scanning or
arly awareness and alert activities. Thus, the authors chose 1479
ndividual indications corresponding to 1371 unique technologies
45% of them were drugs and 23% were devices) as the output
easure for innovation. Overall, they suggest a weak association
etween innovation and disease burden in terms of disability-ad-
usted life-years (DALYs). Nonetheless, the article raised several
ssues but failed to cite some relevant articles published in the last
years in this field [2–7].
The authors argue that “[o]nly Lichtenberg used output mea-
ures of innovation and found a positive relationship [with disease
urden] among developed countries (. . .) based primarily on phar-
aceuticals launched; [and that] drugs currently on sale and rel-
vant published articles were used as innovation outcomes in ad-
itional analyses, but these were limited to the United States and
ancer, respectively” [1]. In this regard, the authors failed to cite a
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Fig. 1 – Correlation between DALYs and new technologies fo
adjusted life-years.report (published in 2010) with some degree of overlap, in which
we further discussed questions about the current extent of the
dilemma in pharmaceutical innovation [7,8]. In our work [7], the
full cohort of human-use drugs authorized by the European Med-
icines Agency (1995–2009) was evaluated. We particularly found
that there was a positive correlation between DALYs and new drug
development. Interestingly, the main disease categories in terms
of the number of innovative drugs were cancer, infectious dis-
eases, and blood and endocrine disorders (accounting for 47% of
new molecules). Some conditions appeared to be neglected (re-
lated to the disease burden generated in the population) as in the
case of neuropsychiatric disorders, cardiovascular diseases, respi-
ratory diseases, and so on. Conversely, in the study by Martino and
colleagues, the authors found that the main disease categories in
terms of the number of innovative technologies were cancer, car-
diovascular diseases, and neuropsychiatric disorders. Comparing
our correlation coefficients with those obtained by Martino and
colleagues, the magnitude of the association between DALYs and
innovation was weaker in our study: correlation coefficients for
developed high-income countries of 0.61 (P  0.006) versus 0.72
(P  0.001). There are, however, several important differences be-
tween studies. We studied drugs (new molecules and marketing
authorizations), whereas Martino and colleagues studied technol-
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988 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 8 7 – 9 8 9ogies including devices and diagnostics as well. Our analyses fo-
cused only on the main indications matched with the categories of
the disease classification system defined in the Global Burden of
Disease (GBD) study, whereas Martino and colleagues focused on
all therapeutic indications for a technology (e.g., each of the mul-
tiple different indications for a monoclonal antibody were consid-
ered as equally significant), which may not always be representa-
tive of innovation. The authors correctly observe, as we have
previously documented in cost-effectiveness research [6], that dis-
aggregating broader categories into specific diseases further
weakened the association. We believe that the most important
issue of Martino and colleagues’ study, however, is that there is
some reason to believe that more misclassification has occurred,
particularly among “other” subcategories (e.g., “other cardiovas-
cular diseases” and “other malignant neoplasms”) than in broader
categories. We recognize that some arbitrary nature is involved in
classifying technologies into specific disease conditions, and re-
searchers may have classified them in a different way. They
showed that nearly 40% (507 of 1371) of the specific disease indi-
cations accounting for the highest numbers of technologies were
paradogically “unspecific” ones. As they mentioned, “other cardio-
vascular diseases” and “other malignant neoplasms” had the
higher number of innovations (150 and 85, respectively), suggest-
ing that “innovation is disproportionately strong in cancer and
nonischemic heart disease.”
In the GBD 1990 study [9], one of the most significant barriers to
ccurately determine the cause of disease burden was the wide-
pread use of nonspecific cause of death codes, such as those for
ll-defined cardiovascular, cancers, and injury codes. Recent arti-
les [10,11] stress that garbage codes negatively impact the public
ealth utility of cause-of-death data. Correction algorithms were
pplied in the GBD study to resolve problems of miscoding for
ardiovascular diseases (mainly involving redistribution of deaths
oded to heart failure, ventricular dysrhythmias, or ill-defined
eart disease) or cancer (involving redistribution of deaths coded
o secondary sites or ill-defined primary sites). Particularly, heart
failure was not an underlying cause of death according to the
GBD definition but rather an intermediate cause of death with a
diverse range of possible underlying causes of death. Instead
heart failure was classified under coronary heart disease. Sim-
ilarly, cancer deaths coded for malignant neoplasms of other
and unspecified sites including those whose point of origin can-
not be determined and secondary and unspecified cancers were
redistributed across the malignant neoplasm categories within
each age-sex group [12–14].
Therefore, miscoding and misclassification may have had a
lear impact on their study findings at the level of specific dis-
ases, and we believe that results should be viewed carefully. To
emonstrate that in part, we present an alternative version of
heir Figure 2 excluding “other (nonspecific) conditions” (with a
election of highest ranking specific causes for reported technol-
gies from Table 2 in the article), illustrating that there was no
vidence in the data of a true correlation between DALYs and in-
ovation for particular disease conditions (R2 linear  0.06; corre-
lation coefficient r  0.24; P  0.17) (Fig. 1).
Finally, we strongly disagree with the authors’ most surprising
conclusion that “[t]he results do not support previous reports of a
positive relationship between burden of disease and innovation,
but accord with evidence of notable discrepancies among key
groups.” Perhaps, Martino and colleagues may wish to reconsider
their results and conclusions in light of all the above.
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